Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand

  • Published : 2006.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7,8 and 9 (P= 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.

Keywords

References

  1. Adak T, Valecha N, Sharma VP (2001) Plasmodium vivax polymorphism in a clinical drug trial. Clin Diagn Lab Immunol 8: 891-894 https://doi.org/10.1128/CDLI.8.5.891-894.2001
  2. Anklesaria PS, Ashar VJ, Kshirsagar NA, Gupta KC (1994) Comparison of the effect of compound CDRI 80/53 [N1-(3 acetyl-4-5-dihydro-2 furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] with primaquine on human erythrocytes in vitro. In Tropical Diseases: Molecular Biology and Control Strategies, Kumar S, Sen AK, Dutta GP, Sharma RN (eds.). p 256-261, Publication and Information Directorate, Council of Scientific and Industrial Research, New Delhi, India
  3. Baird JK (2004) Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075-4083 https://doi.org/10.1128/AAC.48.11.4075-4083.2004
  4. Baird JK, Hoffman SL (2004) Primaquine therapy for malariamalaria. Clin Infect Dis 39: 1336-1345 https://doi.org/10.1086/424663
  5. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL (1997) Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621-626 https://doi.org/10.4269/ajtmh.1997.56.621
  6. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T (1994) High dose of primaquine in primaquineresistant vivax malaria. Trans R Soc Trop Med Hyg 88: 218-219 https://doi.org/10.1016/0035-9203(94)90305-0
  7. Chareonviriyaphap T, Bangs MJ, Ratanatham S (2000) Status of malaria in Thailand. Southeast Asian J Trop Med Public Health 31: 225-237
  8. Dutta GP, Puri SK, Bhaduri AP, Seth M (1989) Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg 41: 635-637 https://doi.org/10.4269/ajtmh.1989.41.635
  9. Dutta GP, Puri SK, Pandey VC, Seth M, Bhaduri AP, Chatterjee SK, Asthana OP, Gupta KC (1994) New potential anti-malarials: anti-relapse compound CDRI 80/53. In Tropical Diseases: Molecular Biology and Control Strategies, Kumar S, Sen AK, Dutta GP, Sharma RN (eds.). p 276-285, Publication and Information Directorate, Council of Scientific and Industrial Research, New Delhi, India
  10. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon A, Walsh DS (1997) Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 91: 939-943 https://doi.org/10.1080/00034989760338
  11. Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, Chokjindachai W, Viriyavejakul P, Chalermrut K, Walsh DS, White J(1999) Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 93: 225-230 https://doi.org/10.1080/00034989958474
  12. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106 https://doi.org/10.4269/ajtmh.2001.64.97
  13. Puri SK, Dutta GP (1990) Causal prophylactic activity of a new 8-aminoquinoline derivative against Plasmodium cynomolgi B in rhesus monkeys. Indian J Med Res 91: 197-199
  14. Puri SK, Srivastava R, Pandey VC, Sethi N, Dutta GP (1989) Methemoglobin toxicity and hematological studies on malaria anti-relapse compound CDRI 80/53 in dogs. Am J Trop Med Hyg 41: 638-642 https://doi.org/10.4269/ajtmh.1989.41.638
  15. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM, Looareesuwan S (2003) Clinical trial of oral artesunate with or without highdose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 69: 14-18
  16. Srivastava P, Puri SK, Dutta GP, Pandey VC (1993) Effect of the anti-malarial agents primaquine and (N1-3-acetyl-4- 5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine on oxidative stress and anti-oxidant defences in mice. Biochem Pharmacol 46: 1859-1860 https://doi.org/10.1016/0006-2952(93)90341-S
  17. Valecha N, Adak T, Bagga AK, Asthana OP, Srivastava JS, Joshi H, Sharma VP (2001) Comparative anti-relapse efficacy of CDRI compound 80/53 (bulaquine) vs primaquine in double blind clinical trial. Curr Sci 80: 561- 563
  18. Wilairatana P, Silachamroon U, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, Phumratanaprapin W, Srivilirit S, Looareesuwan S (1999) Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 61: 973-977 https://doi.org/10.4269/ajtmh.1999.61.973